# Genomic Applications Partnership Program (GAPP) – National Stream and BC Stream (BC-GAPP)

 **LETTER OF INTENT**

## General Instructions

**Note: This form is specific for teams applying to GAPP or BC-GAPP through Genome BC.** Teams interested in applying to GAPP through a different region are encouraged to contact the respective regional Genome Centre.

This Letter of Intent (LOI) form will be used by Genome BC to assess the proposed project’s fit for the National GAPP and/or BC-GAPP. If invited to proceed with the National GAPP, Genome BC will initiate an LOI for you through Genome Canada’s [Proposal Central](https://proposalcentral.com/) online portal for you to complete the process.

Refer to Genome Canada’s [Guidelines for Funding](https://genomecanada.ca/about/corporate-policies-and-statements/funding-guidelines-and-policies/) and to the [GAPP Funding Opportunity](https://genomecanada.ca/funding/genomic-applications-partnership-program/) for more details.

# TITLE PAGE

|  |  |
| --- | --- |
| **Project Title** |  |
| **Total budget amount** | $ |
| **Genome Canada Ask** *(max 1/3 of total budget)* | $ |
| **Genome BC Ask** *(max 1/6 of total budget)* | $ |
| **Intended GAPP Stream** *(National GAPP/BC-GAPP/either)* |  |
| **Project start and end dates** |  |

|  |
| --- |
|  |
| **Researcher/Administrative Project Leader:** | **Receptor Project Leader:** |
| **Name**  |  | **Name** |  |
| **Affiliation** |  | **Affiliation** |  |
| **Address** |  | **Address** |  |
| **E-mail** |  | **E-mail** |  |

# RECEPTOR INFORMATION

|  |
| --- |
| **Receptor Eligibility Questions:** **Provide a response to the questions below (maximum 300 characters per response)**  |

|  |
| --- |
| **Ownership** - Briefly describe how the receptor meets the requirement of being a majority Canadian-owned for-profit enterprise, as per Appendix A of the [GAPP funding opportunity](https://genomecanada.ca/wp-content/uploads/2025/06/GAPP-National-Stream-Funding-Opportunity-2025-FINAL-EN.pdf) |
| Response:  |
| **Control** - Briefly describe how control of the receptor is exercised in Canada, including who holds decision-making authority and how this meets the requirement of being more than 50% controlled by Canadian citizens, permanent residents, or eligible Canadian-owned entities. |
| Response:  |

PROJECT INFORMATION:

|  |
| --- |
| **Impact statement:** State the overall goal and expected impact of the project (maximum 100 characters) |
|  |
| **Project Sector(s):** * **Primary** sector**:** Please select one primary project sector that best fits the proposed project
* **Other** sector(s): Please select other project sector(s) that apply to the proposed project
 |
| **Agriculture/agrifood \_\_\_\_** | **Energy \_\_\_\_** | **Environment \_\_\_\_** |
| **Forestry \_\_\_\_** | **Human Health \_\_\_\_** | **Mining \_\_\_\_** |
| **Fisheries/Aquaculture \_\_\_\_** | **Data/Technology \_\_\_\_** | **Other \_\_\_\_\_\_\_\_\_\_** |
| **Keywords:** In the text boxes below, please provide comma-separated keywords associated with the application. The terms will be used for statistical and administrative purposes, e.g., identifying appropriate reviewers and oversight experts. Please use specific and validated terms. |
| Research Areas(limit 100 characters) |  |
| Technology(limit 100 characters) |  |
| Genomics in Society*Optional*(limit 100 characters) |  |

**LOI QUESTIONS**

|  |
| --- |
| 1. **What is the receptor’s need or opportunity? (max 500 characters)**
	1. **State the value proposition of the primary innovation, with reference to the competitive landscape (if applicable), describing how the innovation will benefit the receptor and/or Canadian society (e.g., revenue/savings generated, jobs created, capacity built, improved outcomes, etc.).**
 |
|  |
| 1. **What is the proposed innovation and its feasibility? (max 1000 characters)**
	1. **Describe the genomics-based or enabled biotechnological innovation, highlighting project goals and clearly demonstrating how genomics is integrated into the project’s activities and proposed outcomes.**
	2. **Summarize the major methods to be used for achieving the project goal(s) and deliverables, with quantitative performance targets, and key actions at project milestones where applicable.**
 |
|  |
| 1. **What is the market opportunity and how is it validated? (max 750 characters)**
 |
|  |
| 1. **What is your approach to commercializing the innovation or extracting the value from innovation? (max 750 characters)**
 |
|  |
| 1. **Why should investors be confident that the team will deliver on project objectives? (max 500 characters)**
	1. **Describe how the partnership is structured and how it leverages the resources and expertise of the partners.**
 |
|  |

|  |
| --- |
| **Appendix I – Project budget and co-funding summary** |
| **A) Budget summary** |  |  |  |
| This budget is an estimate only. An itemized budget will be required with the full proposal. |
|  |  |  |  |  |
| **Project budget (CDN$)** | **Year 1** | **Year 2** | **Year 3** (GAPP projects only) | **Total / category** |
|
| Activity 1 |   |   |   |   |
| Activity 2 |   |   |   |   |
| Activity 3 |   |   |   |   |
| Activity 4 |   |   |   |   |
| Project Management |   |   |   |   |
|   |   |   |   | **Total project** |
| **Total / year** |   |   |   |   |
|  |  |  |  |  |
|  |  |  |  |  |
| **B) Co-funding summary** |  |  |  |
| Genome Canada will fund up to one third of approved eligible costs for new R&D activities that are an integral part of the Genome Canada approved project. |
| The remaining two thirds of the funding must be secured through co-funding, with at least one third provided by the private sector. |
|  |  |  |  |  |
| **Funding source** | **Type** | **Status** | **Total contribution (CDN$)** |  |
| Genome Canada | Unrestricted cash  | Awaiting response |  |  |
| Genome BC | Unrestricted cash | Awaiting response |  |  |
| Receptor |   |   |   |  |
| Organization 1 |   |   |   |  |
| Organization 2  |   |   |   |  |
|   |   |   |   |  |
| **Total** |   |  |
|  |  |  |  |  |
| (1) Types of co-funding can be: unrestricted cash, restricted cash (as specified by funder) or in-kind contribution. |
| (2) Status of co-funding can be: received, committed, awaiting response or yet to apply.  |  |